

RESEARCH

Open Access



Egocentric network characteristics of people who inject drugs in the Chicago metro area and associations with hepatitis C virus and injection risk behavior

Mary Ellen Mackesy-Amiti^{1*} , Joshua Falk², Carl Latkin³, Maggie Kaufmann⁴, Leslie Williams¹ and Basmattee Boodram¹

Abstract

Background: Hepatitis C (HCV) infection has been rising in the suburban and rural USA, mainly via injection-based transmission. Injection and sexual networks are recognized as an important element in fostering and preventing risky behavior; however, the role of social support networks has received somewhat less attention.

Methods: Using baseline data from an ongoing longitudinal study, we examined the composition and structure of injection drug use (IDU), sex, and social support networks of young people who inject drugs (aged 18–30) and their injection network members. Lasso logistic regression was used to select a subset of network characteristics that were potentially important predictors of injection risk behaviors and HCV exposure.

Results: Several measures of IDU, sexual, and support network structure and composition were found to be associated with HCV exposure, receptive syringe sharing (RSS), and ancillary equipment sharing. Gender and sexual relationships were important factors for all risk behaviors. Support network characteristics were also important, notably including a protective effect of majority Hispanic support networks for RSS and HCV exposure. Both IDU network residence heterogeneity and support network geography were associated with injection equipment sharing.

Conclusions: The associations of IDU and support network geography with equipment sharing highlight the need to extend harm reduction efforts beyond urban areas. Greater understanding of support network influences on risk behavior may provide important insights to strengthen the benefits of harm reduction. In considering the probability of HCV transmission, it is important to consider setting and network structures that promote propagation of risk.

Keywords: Hepatitis C, Injection drug use, Risk behavior, Egocentric networks, People who inject drugs, Injection network, Support network, Network structure, Geography

Introduction

Injection drug use (IDU) is the primary mode of hepatitis C (HCV) transmission in developed countries such as the USA [1], with an estimated 67% of all HCV infections attributable to IDU in 2019 [2]. Fueled by the opioid epidemic, HCV incidence has increased fourfold between 2008 and 2019 [3], primarily driven by young people who inject drugs (PWID)

*Correspondence: mmamiti@uic.edu

¹ Division of Community Health Sciences, School of Public Health, University of Illinois at Chicago, 1603 W. Taylor St, Chicago, IL 60612, USA
Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

from non-urban areas [4–9], and HCV-related deaths have now surpassed the total combined deaths from 60 other infectious diseases in the USA, including HIV and late-stage HIV-related illness [10].

Social network factors have been studied for their role in drug equipment sharing behavior (reviewed in De et al. [11]) and HIV risk [12–14], with fewer studies focused on HCV among US PWID [15, 16]. To achieve the World Health Organization's (WHO) goal of reducing new chronic infections by 90% and mortality by 65% by 2030 [17] in the USA, innovative strategies are needed, as the USA continues to lag behind most high-income countries in achieving this goal [18]. HCV transmission through IDU necessarily involves close personal interactions among PWID. In addition to an injection risk network that is linked by syringe-sharing behaviors, most PWID are embedded in other (e.g., sexual and support) networks that may overlap with their IDU networks to varying degrees. Characteristics and structure of these networks can affect the likelihood of engaging in risky behaviors that are associated with HCV risk [11, 19–22] and provide insight into network-based mitigation interventions.

Using baseline data from an ongoing longitudinal egocentric network study of young PWID and their injection, sexual, and support networks from a large metro area, we report on two gaps in the current body of research. First, building on previous work by our team [15, 23], to our knowledge this is the first study to report on the injection, support, and sexual network characteristics and structure of the emerging population of young, predominantly non-Hispanic white suburban PWID from a large metropolitan area. Second, while network factors have been extensively examined in relation to HIV risk and interventions, there is a dearth of studies that have focused on hepatitis C; no prior study to our knowledge has simultaneously examined the role of injection, sexual, and support network size, attributes, and structure in association with injection risk behaviors and HCV infection in this population. Specifically, we examine associations between risky injection behavior (e.g., receptive syringe sharing) and aggregate measures of composition and structure of egocentric injection, support, and sexual activity networks among young urban and suburban PWID. Our study will provide a better understanding of the network factors among young PWID, the population primarily driving HCV incidence in the USA, toward achieving the World Health Organization's goal of HCV elimination [17].

Methods

The alter-ego study is an ongoing (2017-) longitudinal network-based study of young (aged 18–30) PWID (egos) and their injection network members (alters). Baseline interview data were used for the analysis.

Eligibility

To be eligible, ego participants (i.e., initial participants who were asked to recruit their network members) had to be (1) 18–30 years old, (2) injected drugs at least once in past 30 days, (3) willing to recruit PWID ≥ 18 years old at baseline with whom they injected drugs in the past 6 months (i.e., injection network members), (4) willing to be tested for HIV and HCV, and (5) residing in the Chicago Metropolitan Statistical Area in the past 12 months. The injection alters were eligible if they were (1) ≥ 18 years old and (2) had injected drugs with the ego in the past 6 months. Current IDU was verified by experienced study staff checking for injection stigmata and, if questionable, using a standardized procedure to evaluate participant knowledge of the injection process. Age was verified with a driver's license or a state ID card. Project staff offered to assist those without identification in obtaining it. Figure 1 shows the sample generation process.

Ego recruitment

The study was conducted at two field sites of a community outreach center located in Chicago, Illinois, USA, that has been providing services (e.g., syringe service programs; and HIV and HCV counseling, testing, and case management) and conducting research on people who use illicit substances for over 30 years. The field sites are located in areas that have rates above the city's average for HIV/AIDS, sexually transmitted infections, viral hepatitis, and arrests for drug-related offenses and attract both urban and suburban PWID. We recruited most egos from the syringe services program (SSP) at these field sites. In addition, SSP-recruited participants were screened to ascertain if they obtained syringes at the SSP for other people who reside in the suburbs. Those who did were offered a coupon to refer to the study an age-eligible peer who did not use the SSP or purchase/use drugs in Chicago. To encourage peer-recruited PWID to participate, we used a mobile outreach van staffed with an interviewer/phlebotomist, to conduct data collection off-site near the recruit's residence or other mutually agreed upon locations. Alternative outreach methods targeting non-SSP suburban PWID included direct recruitment in drug market areas and at community health events using an outreach van, flyers posted at community-based organizations serving PWID, and social media and other




Fig. 1 Ego and alter sample generation schema

online ads. Screening and enrollment of non-SSP PWID from drug market areas were done by indigenous field staff with extensive experience working in these areas and recruiting for similar studies.

Alter recruitment

At their baseline visit, we asked each ego participant to recruit up to five alters in their core injection network, defined as people with whom they injected drugs at least once in the past six months, using recruitment coupons that provided information about the study and were linked to the recruiting ego via alphanumeric code. Coupons could only be redeemed by alters named by an ego participant during their survey. Data collection from alters was required to occur within 6 months of the ego’s baseline visit.

Procedures

All participants (egos and alters) completed a process of informed consent. All study procedures were approved by an Institutional Review Board at the University of Illinois at Chicago. Participants received compensation of \$20/hour for the interview. Most participants completed the survey within a 2.5 h session that included a break (average \$50). In addition to hourly compensation for interviews, egos were reimbursed \$10 for each alter enrolled.

All participants received HIV and HCV testing and counseling. All services (e.g., SSP; HCV and HIV testing,

counseling, and case management; and linkage to medical care) were made freely available to all PWID screened, regardless of study enrollment.

Participants completed a baseline computer-assisted interviewer-administered questionnaire, including background demographics, substance use, HCV testing, injection-related behaviors, and other measures. Egonet data were then collected from participants using GENSI software [2016] [24]. The survey is touch screen enabled, and the participant can tactilely participate in the collection of network data via the “binning” of software-generated nodes which represent the members of their IDU, sex, and support networks, with the interviewer. The interview begins with the participant being asked to identify and generate their injection, sexual, and social support networks. They are first asked to generate their total networks (anyone they have injected with, had sex with, or received support from at least once in the past six months). They are then asked to report the gender, age, primary method of drug use and substance, race/ethnicity, and county of residence for each. For social support network members, participants are asked what their relationship is to the network member (friend, relative, etc.). Once they have generated the total network, they are asked to identify which of the members are in their core injection networks, core social support networks, and core sex networks (see definitions below). The remainder of the survey focuses on these core networks. Starting with the participants’ IDU core, they are asked

questions related to each member and are asked to “bin” the bubbles that represent their network members in the appropriate answer bin. They are also asked how well the members of their 3 networks know each other to collect the strength of tie for each relationship.

Network survey

Injection network

Participants were asked to identify people who they used drugs with in the past six months (total injection network). Among those, they were then asked to identify a core injection network of up to ten people who they used drugs with more than once in the past six months. Data on the injection network were collected by proxy for the total and core injection network, and directly from up to five alters identified and recruited by egos.

Support network

Participants were asked to identify people who provided support to them in the past six months (total support network). This included “anyone you could talk to about things that are personal and private or get advice from if a situation came up” (personal support), and “anyone that would let you stay at their place if needed” (shelter support). Among their support network, they were then asked to identify a core support network of up to ten people who provided the most support in the past six months.

Sex network

Participants were asked to identify people they had sex with in the past six months, including vaginal, anal, or oral sex. Among these, they were then asked to identify a core sex network of up to ten people who the participant had sex with more than once in the past six months.

Individual measures (ego and alters)

Demographics

Self-reported gender, age, race, and Hispanic/Latinx ethnicity were collected. Gender was reported as male, female, transgender, or other. Multiple categories could be selected for race; ethnicity was indicated separately as Hispanic/Latinx or not Hispanic/Latinx. Race and ethnicity were also combined to create an indicator variable with mutually exclusive categories: non-Hispanic white (white only), non-Hispanic Black (including mixed), Hispanic (any race), and non-Hispanic other race. Employment was assessed based on responses to the question “During the last 6 months, did you receive any money from any of these sources?” Participants who indicated that they received money from a regular job (full or part-time) or self-employment were classified as employed. Egos were similarly asked to provide sociodemographic

information on their alters as part of the network interview.

HIV and HCV status

Rapid HIV and HCV antibody (Orasure Technologies, 2004, 2011) testing was used to determine prevalence of exposure (past or current infection) for egos and recruited alters.

Syringe and equipment sharing

Injection behavior was assessed on a 5-point Likert-type scale (never, less than half the time, about half the time, more than half the time, or always). Questions assessed receptive syringe sharing (RSS) (“When you shot-up in the last 6 months, how often did you use a syringe that you know for sure had been used before by someone else?”), equipment sharing (“When you injected drugs in the last six months, how often did you use any of the following items with other people? (a) drawn from the same cooker, (b) used the same cotton, (c) used the same rinse water”), and backloading (“In the last six months, how often did you inject with a syringe AFTER someone else has squirted drugs into it from their syringe?”). Equipment sharing was coded as the maximum of the three items (cookers, cottons, water). Each of these measures was dichotomized to indicate any behavior in the past six months.

Network measures

Summary measures of ego network size, composition, and structure were computed for the IDU, sex, and support networks, which are defined and described in an additional table (see Additional file 1: Table S1). Ego–alter tie strength was based on frequency of contact, assessed by asking “How often do you talk to or see this person?” with options on a 6-point scale from every day to less than once a year. The last 3 categories were collapsed into once a month or less to create a 4-point scale. Alter–alter tie strength was based on the ego’s assessment of how well the two people knew each other, on a 4-point scale with anchors 1 = “casual acquaintance” and 4 = “very close relationship.”

All network measures were computed using NetworkX version 2.4 [25], except modularity, which was computed using the *igraph* R package version 1.2.5 [26]. Modularity was computed by finding the network partition that maximizes Newman’s Q. Hierarchy was implemented following Eq. 2.9 of Burt [27]. For measures that rely on distance rather than tie strength (for example, betweenness and closeness centrality), the scale was reversed, so that strongest ties were coded with a distance of 1 and weakest ties with a distance of 4. Average and local clustering, average distance, centrality, centralization, constraint,

effective size, efficiency, and hierarchy were all computed both with real-valued edge weights based on tie strength and with binary edge weights based on presence/absence of a tie. Centralization measures and hierarchy are undefined when ego has degree one; these were recoded to zero for analysis.

Imputation of missing ties

Missing ties and tie strengths were imputed using sklearn version 0.22.1 [28]. For ego–alter tie strength, a random forest classifier was trained using all available ego–alter tie strengths, with ego sex, alter sex, and relationship types as features. Tie strength was randomly sampled for missing data according to the predicted probability distribution from the classifier. For alter–alter ties and tie strengths, a random forest classifier was trained using all alter–alter networks without missing data, with the sex of each alter and the relationship types between ego and each alter as features. Tie presence and strength were randomly sampled according to the predicted probability distribution from the classifier.

Covariates and outcomes

Covariates included 40 injection network variables, 40 support network variables, and 2 sex network variables, plus ego demographic variables: age, sex (female vs. male), and binary indicators of white, Black, and Hispanic. Risk behavior outcomes were binary indicators of RSS, equipment sharing, and backloading in the past six months.

Sample

Figure 1 summarizes the unique participants (egos and alters). Of the 177 egos who completed the baseline study visit and provided proxy data on their total and core injection, sexual, and support networks, 9 were excluded: 6 did not have any support network, and 3 had missing data on key variables. Of the 117 alters who were recruited into the study and completed the baseline study visit in person, 16 were excluded: 9 had not injected drugs in the previous 6 months, 6 did not have a support network, and 1 had an incomplete network interview. In addition to providing data on relationship with egos, recruited alters also became second wave egos. The final analytic sample includes 168 ego and 101 alter (second wave ego) participants (total = 269).

Analysis

Given the large number of network measures potentially associated with risk behavior, some of which are highly correlated with one another, we conducted adaptive lasso logistic regression (29, 30). The advantage of lasso regression is the k-fold cross-validation, which estimates

prediction error by resampling to select potentially important predictors of HCV antibody positive status and injection risk behavior from a large set of network variables. Lasso regression is a supervised machine-learning method in which the goal is to obtain the subset of predictors that minimizes prediction error. The lasso procedure performs both variable selection and regularization, using shrinkage to select a subset of predictors, which prevents overfitting and encourages simple sparse models [31, 32]. Analyses were conducted using Stata (v. 16).

Adaptive selection in Stata uses cross-validation (CV) to select lambda (the shrinkage parameter), but multiple lassos are performed. In the first lasso, a lambda is selected, and penalty weights are constructed from the coefficient estimates. Then, these weights are used in a second lasso where another lambda is selected. Variables with zero coefficients are discarded after each successive lasso, and variables with nonzero coefficients are given penalty weights designed to drive small coefficient estimates to zero in the next step. CV is done by dividing the data randomly into folds. One fold is chosen and then a regression is fit on the other folds using the variables in the model for that lambda. With these new coefficient estimates, a prediction is computed for the data of the chosen fold. The mean squared error (MSE) of the prediction is computed. This process is repeated for the other folds. The MSEs from all folds are then averaged to give the value of the CV function. We repeated the analysis with 4 different random seeds and increased the number of folds until a result was replicated consistently.

HCV and risk behavior outcomes (RSS, equipment sharing, and backloading) were regressed on the 40 injection network variables, 40 support network variables, 2 sex network variables, ego age, sex (female vs. male or undetermined), and binary indicators of white, Black, and Hispanic.

Exploratory analysis

We conducted post hoc logistic regression analyses and computed predicted probabilities to explore the relationships between selected predictors and outcomes.

Sensitivity analysis

We conducted sensitivity analyses to compare the results using imputation with alternative strategies for missing data, including (1) listwise deletion and (2) imputation of ego–alter tie strengths only, treating missing alter–alter ties as nonexistent.

Table 1 Characteristics of participants ($n = 269$)

	<i>n</i>	%
Gender		
Male	199	74%
Female	69	26%
Transgender	1	0.4%
Race/ethnicity		
NH white	162	60%
NH Black	18	7%
Hispanic (all races)	71	26%
NH other	18	7%
Age		
18–30	201	75%
31–40	47	17%
> 40	21	8%
Mean (SD)	30.1 (7.5)	
Range	[18–64]	
Residence		
Cook county	209	78%
Outer suburbs	60	22%
Employed ^a		
No	159	59%
Yes	110	41%
HCV antibody status ^b		
Positive	84	31%
Negative	173	64%
Receptive syringe sharing		
No	154	57%
Yes	115	43%
Shared cooker past 6 m		
No	73	27%
Yes	195	72%
Backload past 6 m		
No	169	63%
Yes	100	37%
Participant type		
Ego	171	64%
Alter	98	36%

^a Received money from a regular job (full or part-time) or self-employment

^b Baseline rapid antibody test; 12 missing due to COVID-19 interruption. Baseline HIV positive 1.2% ($n = 3$)

Results

Table 1 shows the demographic characteristics of the 269 participants included in the analysis. One person identified as transgender; in calculating gender homophily of the network, they were treated as a third gender. HCV antibody positive prevalence was 18% among Hispanic participants, compared to 36% among non-Hispanic white, 39% among non-Hispanic Black, and 56% among participants of mixed or other race ($\chi^2 = 11.30$, $p = 0.01$).

Thirty-four participants (12%) had incomplete network data due to a software malfunction or interviewer error early in the study period, resulting in a total of 45 ego–alter tie strengths ($n = 16$ participants) and 163 alter–alter ties ($n = 27$ participants) that were not recorded. Missing ties were imputed as described above.

Networks

Summary statistics for the IDU, support, and sexual network measures are presented in Table 2. Additional summary statistics for these three networks are reported in an additional table (see Additional file 2: Table S2). Mean IDU network degree was 3.9 (SD 2.4), while mean support network degree was 2.2 (SD 1.4). Among the 80% of participants with at least one sex partner ($n = 216$), degree of the sex network ranged from one to nine with a mean of 1.8 (SD 1.3), and mean multiplexity of sex partners was 1.9 (SD 0.7). Support networks had greater tie density, tie strength, and race/ethnicity homophily compared to injection networks.

Lasso regression

The results of the lasso regression analysis with 87 covariates are shown in Table 3. The out-of-sample deviance ratio is an estimate of the prediction performance of the model on a new sample relative to the null model. Consistent results were obtained with 50 folds for HCV status and 80 folds for risk behaviors. Being white was significant in the models for RSS and equipment sharing and was the only ego demographic variable selected.

RSS was negatively associated with valued measures of efficiency and closeness centrality in the injection network, and positively associated with injection network gender heterogeneity (mixed gender network) and sex partner multiplexity. Support network older age and greater proportion Hispanic were negatively associated with RSS. Equipment sharing was positively associated with injection network residence heterogeneity (mixed Cook and non-Cook county), and negatively associated with injection network age, gender homophily, efficiency (binary), and constraint (valued). Having a greater proportion of support network members who lived in Cook County was also negatively associated with equipment sharing. The only network variable predictor selected in the model for backloading was injection network gender heterogeneity which was positively associated with a sixfold greater likelihood of backloading. HCV antibody positive status was associated with older age of the IDU network, and negatively associated with percent Hispanic in both the IDU and support network. HCV positivity was also negatively associated with support network gender heterogeneity.

Table 2 Summary statistics for injection, support, and sexual network measures (*n* = 269)

Variable	Injection				Support				Sexual ^a			
	Mean	SD	Min	Max	Mean	SD	Min	Max	Mean	SD	Min	Max
Size (degree)	3.94	2.4	1.0	10.0	2.17	1.4	1.0	10.0	1.80	1.3	1.0	9.0
Percent male	0.70	0.3	0.0	1.0	0.46	0.4	0.0	1.0	0.28	0.4	0.0	1.0
Percent white	0.62	0.4	0.0	1.0	0.66	0.4	0.0	1.0	0.60	0.4	0.0	1.0
Percent Black	0.13	0.3	0.0	1.0	0.10	0.3	0.0	1.0	0.10	0.3	0.0	1.0
Percent Hispanic	0.20	0.3	0.0	1.0	0.19	0.4	0.0	1.0	0.24	0.4	0.0	1.0
Percent employed	0.32	0.3	0.0	1.0	0.61	0.4	0.0	1.0	0.50	0.4	0.0	1.0
Percent reside in CC	0.73	0.4	0.0	1.0	0.61	0.4	0.0	1.0	0.61	0.4	0.0	1.0
Alter mean age	32.70	6.4	19.5	58.0	40.70	12.0	19.5	74.0	30.14	7.7	18.0	61.5
Gender homophily	0.58	0.3	0.0	1.0	0.41	0.4	0.0	1.0	0.04	0.2	0.0	1.0
Age homophily	0.54	0.4	0.0	1.0	0.50	0.4	0.0	1.0	0.60	0.5	0.0	1.0
Race/ethnicity Homophily	0.59	0.4	0.0	1.0	0.69	0.4	0.0	1.0	0.57	0.5	0.0	1.0
Residence homophily	0.69	0.4	0.0	1.0	0.60	0.4	0.0	1.0	0.61	0.4	0.0	1.0
Mean strength of ties	3.08	0.6	1.0	4.0	3.43	0.7	1.0	4.0	3.26	0.9	1.0	4.0
Tie density	0.85	0.2	0.3	1.0	1.59	0.6	1.0	3.0	0.89	0.2	0.2	1.0
Closeness centralization (bin.)	0.29	0.3	0.0	1.0	0.95	0.1	0.5	1.0	0.23	0.4	0.0	1.0
Closeness centralization (val.)	0.37	0.3	0.0	1.0	0.12	0.3	0.0	1.0	0.18	0.3	0.0	1.0
Closeness centrality (val.)	0.60	0.2	0.3	1.0	0.29	0.4	0.0	1.0	0.71	0.3	0.3	1.0
Constraint (bin.)	0.74	0.3	0.2	1.1	0.74	0.3	0.3	1.0	0.87	0.3	0.1	1.1
Constraint (val.)	0.72	0.3	0.3	1.6	0.93	0.2	0.3	1.1	0.86	0.3	0.1	1.5
Mean multiplexity	1.43	0.5	1.0	3.0	0.90	0.2	0.3	1.4	1.92	0.7	1.0	3.0
Efficiency (bin.)	0.57	0.3	0.1	1.0	0.70	0.3	0.1	1.0	0.90	0.2	0.2	1.0
Efficiency (val.)	0.69	0.2	0.2	1.0	0.78	0.2	0.2	1.0	0.93	0.2	0.2	1.0
Gender heterogeneity	0.27	0.2	0.0	0.5	0.21	0.2	0.0	0.5	0.02	0.1	0.0	0.5

Heterogeneity, Blau's Index; bin, binary; val, valued; and CC, Cook County

^a *N* = 216 (53 have no sex partners)


Figure 2 presents network exemplars to illustrate the measures of efficiency, constraint, and closeness centrality. In graph A, ego has high efficiency, because there is no redundancy in the connections. If you removed any edge, the connected alter would be completely isolated from the rest of the network, with no alternative path. In the complete graphs (B and C), there are lots of redundancies in the connections, so efficiency for ego is low. In graph A, constraint on ego is low because ego is connected to many alters which are only connected to each other through ego. In graph B, constraint on ego is high, because the alters are all connected to each other, so ego is only in contact with a single cluster. In graph C, constraint on ego is even higher, because all of ego's alters have stronger ties to each other than to ego, and thus, ego is only in contact with a single highly connected cluster. In graphs A and B, ego has high closeness centrality, since there is a short path between it and every alter. In graph C, ego has low closeness centrality. Its ties to alters are weak, so the distance between ego and any alter is high.

Exploratory analysis

We conducted post hoc logistic regression analysis to explore the relationship between support network mean age and RSS, adjusted for respondent age and non-Hispanic white race/ethnicity. When support network mean age was categorized (18–29, 30–39, 40–49, 50+), the predicted probability of RSS was lower when support network mean age was 50 or above compared to less than 50 (0.27 vs. 0.47; reverse Helmert contrast $\chi^2 = 7.48$, $p = 0.0062$, Bonferroni adjusted $p = 0.0186$). Similarly, we examined the relationship between support network proportion Hispanic and RSS. After examining the distribution of proportion Hispanic, we created a binary indicator to compare majority Hispanic (50% or greater) with majority non-Hispanic. In logistic regression analysis including non-Hispanic white race/ethnicity and support network mean age as covariates, majority Hispanic support network was associated with lower probability of RSS (marginal probability 0.29 vs. 0.47; OR = 0.44, 95% CI 0.23–0.87). Likewise, adjusted for IDU network mean age, having a majority Hispanic support or IDU network had a protective effect on HCV positivity (marginal

Table 3 Penalized coefficients of variables selected in adaptive lasso regression

	Receptive syringe sharing	Equipment sharing	Backload	HCV positive
Demographics				
White	3.249	2.573	–	–
IDU network				
Mean age	–	0.977	–	1.099
Percent Hispanic	–	–	–	0.282
Gender homophily	–	0.560	–	–
Gender heterogeneity	1.539	–	6.102	–
Residence heterogeneity	–	1.829	–	–
Efficiency (binary)	–	0.613	–	–
Efficiency (valued)	0.093	–	–	–
Closeness centrality (valued)	0.403	–	–	–
Constraint (valued)	–	0.186	–	–
Support network				
Mean age	0.973	–	–	–
Percent Hispanic	0.444	–	–	0.476
Percent Cook County	–	0.575	–	–
Gender heterogeneity	–	–	–	0.266
Sex network				
Mean multiplexity	1.356	–	–	–
Lambda	0.003	0.021	0.002	0.004
Out-of-sample deviance ratio	0.086	0.064	0.016	0.084
CV mean deviance	0.086	1.004	1.299	1.158
N	269	268	269	257



probability 0.14 vs. 0.37; OR=0.25, 95% CI 0.11–0.60). Most of the Hispanic participants (70%) in the sample identified as Mexican–American, and this group had a lower HCV positivity prevalence (12.5%) than other Hispanics, and a higher proportion of Hispanic IDU and support network members.

Sensitivity analysis

When missing alter ties were treated as absent, the RSS model selected 6 additional variables, while the equipment sharing, backloading, and HCV models were the same as with imputation. When cases with missing tie data were excluded, the RSS model selected five additional variables, the equipment sharing model omitted injection network efficiency and included IDU degree,

and the HCV model omitted support network gender heterogeneity. The backloading model was the same as with imputation.

Discussion

Our study examined associations of injection, sex, and support network characteristics with HCV infection and risky injection practices. We identified several network characteristics associated with HCV status, RSS, and equipment sharing, including both injection and support network composition variables. RSS and equipment sharing were also associated with certain measures of injection network structure.

Injection network composition

Gender and sexual relationships were clearly important factors for all risk behaviors. Previous research has noted the association between having a sex partner who is also an injection partner (i.e., multiplexity) and greater likelihood of sharing syringes [33–37]. In this study, simply having a mixed gender injection network (high heterogeneity or low homophily) was also associated with increased probability of injection risk behavior and was the only predictor associated with backloading. There may be a tendency for women who inject drugs to rely on a more experienced male IDU partner to prepare the shot as well as purchase the drugs, even outside of a sexual relationship.

Previous research has shown that young PWID are more likely to engage in risky injection behavior compared to older PWID [34, 38, 39]. While the respondent's age was not among the selected variables, the average age of the injection network members was negatively associated with equipment sharing. That is, regardless of the respondent's own age, injecting with young PWID was associated with a greater probability of sharing equipment. While older age is associated with less risky behavior, it is also associated with a greater likelihood of HCV infection simply by accumulation over time. Hispanic ethnicity of the IDU network was associated with a lower likelihood of HCV infection, but was not associated with reported risk behavior. This is consistent with epidemiological evidence of lower HCV prevalence in US Hispanic populations generally, especially Mexican-Americans [2, 40], and highlights the importance of ethnic mixing for exposure risk.

Our previous research found greater injection risk behavior among young PWID who were transient across urban and suburban areas [15, 41]. Here, we similarly found equipment sharing was more likely among PWID with high injection network residence heterogeneity. That is, PWID with injection networks spanning Cook County and suburban areas outside of Cook County were more

likely to report equipment sharing. This is a unique finding that may or may not generalize to other populations, but has implications locally for harm reduction efforts to prevent HCV. Sharing injection equipment other than syringes poses a significant risk for HCV infection [42, 43]. Among PWID with less exposure to harm reduction messages, the risks of equipment sharing may be less salient than those of syringe sharing [44].

Injection network structure

Previous studies have found that syringe sharing is associated with network size and density [11, 19, 45–48]. In this study, we found that low injection network efficiency was associated with greater probability of both RSS and equipment sharing, and efficiency was negatively correlated with both network size and density. Low efficiency reflects a network that is both large and dense, while a high efficiency network is either small, or large and low density. Taking into account the strength of ties gives greater weight to close relationships. In this sample, the valued measure of efficiency, which takes into account the strength of ties, was more strongly associated with RSS, while the binary measure better predicted equipment sharing. PWID with large, dense networks may be optimal candidates for training as peer educators (PE) to reduce their own risk and to disseminate harm reduction information to their peers [49–51]. Evidence suggests that PE training is at least moderately effective for reducing risk behavior [49, 52–54], but it is intensive and therefore costly [55], yet little attention has been given to the selection of PE candidates to maximize outcomes.

Other structural variables found to be associated with risk behavior in our study include (valued) closeness centrality, which was negatively associated with RSS and (valued) constraint negatively associated with equipment sharing. These two measures are significantly positively correlated ($r=0.30$, $p<0.0001$). In an egocentric network, closeness centrality is the reciprocal of the average length of the shortest paths between the ego and each alter, rescaled to range from 0 to 1. Thus, high closeness centrality reflects stronger relationships. It may seem counterintuitive that PWID with stronger ties to their injection network were less likely to report RSS, when at the dyad level PWID are more likely to share syringes with those closer to them [15, 56]. This highlights the importance of distinguishing between dyadic effects and collective network influences and suggests that PWID with a mix of weak and strong ties in their network may be more likely to engage in RSS than those with consistently strong relationships.

We found high constraint was associated with a lower probability of equipment sharing; this was the strongest association with equipment sharing next to non-Hispanic

white race/ethnicity. Constraint measures the extent to which the ego is connected to alters, who are in turn connected to one another, and is highly correlated with tie density. The more alters are connected to one another, the more the ego's behavior may be constrained, as alters can interact with each other without having to go through the ego. The association between constraint and equipment sharing is likely due to selective behavior of the alters having closer ties to one another than to ego.

Support network composition

Interestingly, having older support network members was protective for RSS. Older support network members are likely to be parents and other relatives. Young PWID who are lacking this type of support network may be more likely to engage in risky behavior. A majority Hispanic support network was also associated with a lower likelihood of both RSS and HCV, regardless of the respondent's own ethnicity, though Hispanic participants were more likely to have a majority Hispanic support network. Variability in ethnicity of support and IDU networks may also account for differences among Hispanic subgroups, such as Mexican-Americans and Puerto Ricans. A better understanding of network factors that protect Hispanic PWID might yield novel ideas for reducing risk among non-Hispanic PWID.

A mixed gender support network was also protective for HCV. For equipment sharing, having more support network members who lived in Cook County was protective, suggesting that PWID who migrate into the urban center from outer suburbs may be more likely to engage in risky injection behavior. This relates to the finding noted above that IDU network residence heterogeneity was associated with equipment sharing and highlights the need to extend harm reduction efforts geographically.

Limitations

Over ten percent of respondents had missing network tie data, for which we used imputation. Our sensitivity analysis indicated that imputation of tie data resulted in a more parsimonious model for RSS and made little difference for equipment sharing or backloading. We used lasso regression to identify a set of likely predictors from a large set of variables. This type of analysis does not allow for statistical inference. The predicted strength of the effects is given by the penalized regression coefficients, which are standardized coefficients, but no standard errors or p values are computed. Variable selection is data driven with the goal of prediction rather than explanation. However, this is not necessarily a weakness [57–59]. The results of predictive modeling can stimulate investigation and discovery of causal mechanisms. An integrated approach considering both explanation and

prediction can lead to more robust models with greater generalizability [58].

Conclusions

As in previous research, race/ethnicity, age, gender mixing, and injection network size and density were important influences on injection risk behavior. RSS, but not equipment sharing, was associated with multiplex IDU–sex partner relationships. The associations of IDU and support network geography with equipment sharing highlight the need to extend harm reduction efforts beyond urban areas. We also saw that support network composition may affect injection risk behavior. Greater understanding of these influences may provide important insights to strengthen the benefits of harm reduction. In considering the probability of HCV transmission, it is important to consider both individual risk behaviors and the settings and network structures that promote propagation. In our sample of young urban and suburban PWID, we report on these factors, many of which for the first time.

Harm reduction efforts were successful in significantly reducing HIV among PWID in the USA in the 1990s [60–63]; however, evidence for the impact of harm reduction strategies in reducing HCV transmission among PWID is mixed [64–67]. A recent review showed that SSPs alone have a lower impact in North America compared to Europe, but more positive results were found for combination strategies (SSP and opioid substitution therapy). Because HCV is transmitted much more efficiently than HIV, harm reduction interventions must be scaled up considerably to have an impact. Network-based strategies may help us to scale up more efficiently. Our study elucidated a number of network composition (e.g., age, gender, sexual relationship, ethnicity), network structure (e.g., efficiency, closeness centrality, constraint), and geographic variables (e.g., transience) that were associated with syringe sharing. Given the alarming increases in HCV among US PWID, harm reduction programs that employ network-based strategies may augment impact in the USA to achieve outcomes similar to those in Europe [67]. These may include network-based harm reduction strategies (e.g., provision of the number of syringes by SSPs based on injection network size) or more targeted outreach to high-risk groups (e.g., transient PWID). Given that the USA lags behind other high-income countries in progress toward meeting WHO's HCV elimination goals [68], future research could examine the impact of these strategies in regional microelimination of HCV [69].

Abbreviations

CV: Cross-validation; HCV: Hepatitis C virus; IDU: Injection drug use; MSE: Mean squared error; PWID: People who inject drugs; RSS: Receptive syringe sharing; SSP: Syringe services program.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12954-022-00642-4>.

Additional file 1. Table S1: Definitions of network measures

Additional file 2. Table S2: Additional statistics for network measures

Acknowledgements

We would like to acknowledge and thank the Community Outreach Intervention Projects staff for making this research possible.

Author contributions

MM conceived and conducted the analysis and was a major contributor in writing the manuscript. JF conducted the network analysis to compute the measures of network structure and composition and contributed to writing the manuscript. CL provided essential conceptual feedback to the manuscript. MK contributed to the acquisition of the data and revision of the manuscript. LW contributed to the revision of the manuscript. BB conceived and designed the study and was a major contributor in writing the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by grants from the National Institute on Drug Abuse [grant number R01DA043484] and the National Institute of General Medical Sciences [grant number R01GM121600].

Availability of data and materials

The datasets analyzed during the current study are available from the corresponding author on reasonable request subject to a data use agreement.

Declarations

Ethics approval and consent to participate

Study procedures were approved by the University of Illinois at Chicago Institutional Review Board.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Division of Community Health Sciences, School of Public Health, University of Illinois at Chicago, 1603 W. Taylor St, Chicago, IL 60612, USA. ²Advanced Cyberinfrastructure for Education and Research (ACER), Office of the Vice Chancellor of Innovation, University of Illinois at Chicago, 728 W. Roosevelt Rd., 215A RRB, Chicago, IL 60607, USA. ³Department of Health, Behavior, and Society, Bloomberg School of Public Health, Johns Hopkins University, 615 N. Wolfe St, Baltimore, MD 21205, USA. ⁴Community Outreach Intervention Projects, School of Public Health, University of Illinois at Chicago, 1603 W. Taylor St, Chicago, IL 60612, USA.

Received: 29 November 2021 Accepted: 20 May 2022

Published online: 02 June 2022

References

- Alter MJ. Epidemiology of hepatitis C virus infection. *World J Gastroenterol.* 2007;13:2436–41.
- Centers for Disease Control and Prevention. Viral Hepatitis Surveillance Report – United States, 2019. Atlanta, GA; May 2021. <https://www.cdc.gov/hepatitis/statistics/2019surveillance/index.htm>.
- Ryerson AB, Schillie S, Barker LK, Kupronis BA, Wester C. Vital signs: newly reported acute and chronic hepatitis C cases—United States, 2009–2018. *MMWR Morb Mortal Wkly Rep.* 2020;69:399–404.
- Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, Moore-Moravian L, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤ 30 years, Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. *MMWR Morb Mortal Wkly Rep.* 2015;64(17):453–8.
- Centers for Disease Control and Prevention. Hepatitis C virus infection among adolescents and young adults: Massachusetts, 2002–2009. *MMWR Morb Mortal Wkly Rep.* 2011; 60(17): 537–41.
- Centers for Disease Control and Prevention. Surveillance for Viral Hepatitis—United States, 2011. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention. <http://www.cdc.gov/hepatitis/Statistics/2011Surveillance/index.htm>.
- Centers for Disease Control and Prevention. Viral Hepatitis Surveillance—United States, 2018. July 2020. <https://www.cdc.gov/hepatitis/statistics/SurveillanceRpts.htm>.
- Centers for Disease Control and Prevention. Use of enhanced surveillance for hepatitis C virus infection to detect a cluster among young injection-drug users—New York, November 2004–April 2007. *MMWR Morb Mortal Wkly Rep.* 2008; 57(19): 517.
- Suryaprasad AG, White JZ, Xu F, Eichler B-A, Hamilton J, Patel A, et al. Emerging epidemic of hepatitis C virus infections among young non-urban persons who inject drugs in the United States, 2006–2012. *Clin Infect Dis.* 2014;59(10):1411–9.
- Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising mortality associated with hepatitis C virus in the United States, 2003–2013. *Clin Infect Dis.* 2016;62(10):1287–8.
- De P, Cox J, Boivin J-F, Platt RW, Jolly AM. The importance of social networks in their association to drug equipment sharing among injection drug users: a review. *Addiction.* 2007;102(11):1730–9.
- Latkin C, Kuramoto S, Davey-Rothwell M, Tobin K. Social norms, social networks, and HIV risk behavior among injection drug users. *AIDS Behav.* 2010;14(5):1159–68.
- Young AM, Jonas AB, Mullins UL, Halgin DS, Havens JR. Network structure and the risk for HIV transmission among rural drug users. *AIDS Behav.* 2013;17(7):2341–51.
- Verdery AM, Siripong N, Pence BW. Social network clustering and the spread of HIV/AIDS among persons who inject drugs in 2 cities in the Philippines. *J Acquir Immune Defic Syndr.* 2017;76(1):26–32.
- Boodram B, Mackesy-Amiti ME, Latkin C. The role of social networks and geography on risky injection behaviors of young persons who inject drugs. *Drug Alcohol Depend.* 2015;154:229–35.
- Havens JR, Lofwall MR, Frost SD, Oser CB, Leukefeld CG, Crosby RA. Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. *Am J Public Health.* 2013;103(1):e44–52.
- World Health Organization. Combating hepatitis B and C to reach elimination by 2030: advocacy brief. Geneva, Switzerland; May 2016. Report No.: WHO/HIV/2016.04. <https://apps.who.int/iris/handle/10665/206453>.
- Gamkrelidze I, Pawlotsky JM, Lazarus JV, Feld JJ, Zeuzem S, Bao Y, et al. Progress towards hepatitis C virus elimination in high-income countries: an updated analysis. *Liver Int.* 2021;41(3):456–63.
- Rothenberg RB, Potterat JJ, Woodhouse DE, Muth SQ, Darrow WW, Klodahl AS. Social network dynamics and HIV transmission. *AIDS.* 1998;12(12):1529–36.
- Hahn JA, Evans JL, Davidson PJ, Lum PJ, Page K. Hepatitis C virus risk behaviors within the partnerships of young injecting drug users. *Addiction.* 2010;105(7):1254–64.
- Latkin C, Srikrishnan AK, Yang C, Johnson S, Solomon SS, Kumar S, et al. The relationship between drug use stigma and HIV injection risk behaviors among injection drug users in Chennai, India. *Drug Alcohol Depend.* 2010;110(3):221–7.
- Neaigus A, Friedman SR, Curtis R, Des Jarlais DC, Furst RT, Jose B, et al. The relevance of drug injectors' social and risk networks for understanding and preventing HIV infection. *Soc Sci Med.* 1994;38(1):67–78.

23. Mackesy-Amiti ME, Donenberg GR, Ouellet LJ. Psychiatric correlates of injection risk behavior among young people who inject drugs. *Psychol Addict Behav*. 2014;28(4):1089–95.
24. Stark TH, Krosnick JA. GENSI: a new graphical tool to collect ego-centered network data. *Soc Netw*. 2017;48:36–45.
25. Hagberg AA, Schult DA, Swart PJ. Exploring network structure, dynamics, and function using NetworkX. In: Varoquaux G, Vaught T, Millman J, editors. *Proceedings of the 7th Python in science conference (SciPy2008)*. 2008. p. 11–5.
26. Csardi G, Nepusz T. The igraph software package for complex network research. *Int J Complex Syst*. 2006;1695:1.
27. Burt RS. *Structural holes: the social structure of competition*. Cambridge.: Harvard University Press; 1992.
28. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn: machine learning in python. *J Mach Learn Res*. 2011;12:2825–30.
29. Zou H. The adaptive lasso and its oracle properties. *J Am Stat Assoc*. 2006;101(476):1418–29.
30. Bühlmann P, van de Geer S. *Statistics for high-dimensional data: methods, theory and applications*. Berlin: Springer; 2011.
31. Tibshirani R. Regression shrinkage and selection via the lasso. *J R Stat Soc Ser B (Methodol)*. 1996;58(1):267–88.
32. Hastie TJ, Tibshirani RJ, Wainwright M. *Statistical learning with sparsity: the lasso and generalizations*. Boca Raton: CRC Press; 2015.
33. Sherman SG, Latkin CA, Gielen AC. Social factors related to syringe sharing among injecting partners: a focus on gender. *Subst Use Misuse*. 2001;36(14):2113–36.
34. Thorpe LE, Bailey SL, Huo D, Monterroso ER, Ouellet LJ. Injection-related risk behaviors in young urban and suburban injection drug users in Chicago (1997–1999). *J Acquir Immune Defic Syndr*. 2001;27(1):71–8.
35. Miller M, Neaigus A. Networks, resources and risk among women who use drugs. *Soc Sci Med*. 2001;52(6):967–78.
36. Bailey SL, Ouellet LJ, Mackesy-Amiti ME, Golub ET, Hagan H, Hudson SM, et al. Perceived risk, peer influences, and injection partner type predict receptive syringe sharing among young adult injection drug users in five US cities. *Drug Alcohol Depend*. 2007;91:S18–29.
37. Unger JB, Kipke MD, De Rosa CJ, Hyde J, Ritt-Olson A, Montgomery S. Needle-sharing among young IV drug users and their social network members: the influence of the injection partner's characteristics on HIV risk behavior. *Addict Behav*. 2006;31(9):1607–18.
38. Fennema J, Van Ameijden E, Van Den Hoek A, Coutinho R. Young and recent-onset injecting drug users are a higher risk for HIV. *Addiction*. 1997;92(11):1457–65.
39. Buxton MB, Vlahov D, Strathdee SA, Des Jarlais DC, Morse EV, Ouellet L, et al. Association between injection practices and duration of injection among recently initiated injection drug users. *Drug Alcohol Depend*. 2004;75(2):177–83.
40. Kuniholm MH, Jung M, Everhart JE, Cotler S, Heiss G, McQuillan G, et al. Prevalence of hepatitis C virus infection in US Hispanic/Latino adults: results from the NHANES 2007–2010 and HCHS/SOL studies. *J Infect Dis*. 2014;209(10):1585–90.
41. Boodram B, Hotton AL, Shekhtman L, Gutfraind A, Dahari H. High-risk geographic mobility patterns among young urban and suburban persons who inject drugs and their injection network members. *J Urban Health*. 2018;95(1):71–82.
42. Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. *Am J Epidemiol*. 2002;155(7):645–53.
43. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. *Am J Public Health*. 2001;91(1):42–6.
44. Whiteman A, Burnett J, Handanagic S, Wejnert C, Broz D. Distance matters: the association of proximity to syringe services programs with sharing of syringes and injecting equipment - 17 US cities, 2015. *Int J Drug Policy*. 2020;85:102923.
45. Latkin C, Mandell W, Vlahov D, Oziemkowska M, Celentano D. People and places: behavioral settings and personal network characteristics as correlates of needle sharing. *J Acquir Immune Defic Syndr Hum Retrovirol*. 1996;13(3):273–80.
46. Mandell W, Kim J, Latkin C, Suh T. Depressive symptoms, drug network, and their synergistic effect on needle-sharing behavior among street injection drug users. *Am J Drug Alcohol Abuse*. 1999;25(1):117–27.
47. Latkin C, Mandell W, Vlahov D, Knowlton A. Personal network characteristics as antecedents to needle-sharing and shooting gallery attendance. *Soc Netw*. 1995;17(3–4):219–28.
48. Boodram B, Mackesy-Amiti ME, Khanna A, Brickman B, Dahari H, Ozik J. People who inject drugs in metropolitan Chicago: a meta-analysis of data from 1997–2017 to inform interventions and computational modeling toward hepatitis C microelimination. *PLoS ONE*. 2022;17(1):e0248850.
49. Mackesy-Amiti ME, Finnegan L, Ouellet L, Golub E, Hagan H, Hudson S, et al. Peer-education intervention to reduce injection risk behaviors benefits high-risk young injection drug users: a latent transition analysis of the CIDUS 3/DUIT study. *AIDS Behav*. 2013;17(6):2075–83.
50. Li J, Weeks MR, Borgatti SP, Clair S, Dickson-Gomez J. A social network approach to demonstrate the diffusion and change process of intervention from peer health advocates to the drug using community. *Subst Use Misuse*. 2012;47(5):474–90.
51. Latkin CA, Sherman S, Knowlton A. HIV prevention among drug users: outcome of a network-oriented peer outreach intervention. *Health Psychol*. 2003;22(4):332–9.
52. Medley A, Kennedy C, O'Reilly K, Sweat M. Effectiveness of peer education interventions for HIV prevention in developing countries: a systematic review and meta-analysis. *AIDS Educ Prev*. 2009;21(3):181–206.
53. He J, Wang Y, Du Z, Liao J, He N, Hao Y. Peer education for HIV prevention among high-risk groups: a systematic review and meta-analysis. *BMC Infect Dis*. 2020;20(1):338.
54. Tobin KE, Kuramoto SJ, Davey-Rothwell MA, Latkin CA. The STEP into Action study: a peer-based, personal risk network-focused HIV prevention intervention with injection drug users in Baltimore, Maryland. *Addiction*. 2011;106(2):366–75.
55. Davey-Rothwell M, Owczarzak J, Collins K, Dolcini MM, Tobin K, Mitchell F, et al. Lessons learned from implementing the SHIELD intervention: a peer education intervention for people who use drugs. *AIDS Behav*. 2021;25(11):3472–81.
56. Valente TW, Vlahov D. Selective risk taking among needle exchange participants: implications for supplemental interventions. *Am J Public Health*. 2001;91(3):406–11.
57. Hofman JM, Sharma A, Watts DJ. Prediction and explanation in social systems. *Science*. 2017;355(6324):486–8.
58. Hofman JM, Watts DJ, Athey S, Garip F, Griffiths TL, Kleinberg J, et al. Integrating explanation and prediction in computational social science. *Nature*. 2021;595(7866):181–8.
59. Yarkoni T, Westfall J. Choosing prediction over explanation in psychology: lessons from machine learning. *Perspect Psychol Sci*. 2017;12(6):1100–22.
60. Williams LD, Ibragimov U, Tempalski B, Stall R, Satcher Johnson A, Wang G, et al. Trends over time in HIV prevalence among people who inject drugs in 89 large US metropolitan statistical areas, 1992–2013. *Ann Epidemiol*. 2020;45:12–23.
61. Tempalski B, Lieb S, Cleland C, Cooper H, Brady J, Friedman S. HIV prevalence rates among injection drug users in 96 large US metropolitan areas, 1992–2002. *J Urban Health*. 2009;86(1):132–54.
62. Broz D, Carnes N, Chapin-Bardales J, Des Jarlais DC, Handanagic S, Jones CM, et al. Syringe services programs' role in ending the HIV epidemic in the US: Why we cannot do it without them. *Am J Prev Med*. 2021;61:S118–29.
63. Des Jarlais DC, Kerr T, Carrieri P, Feelemyer J, Arasteh K. HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks. *AIDS*. 2016;30(6):815–26.
64. MacArthur GJ, van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, et al. Interventions to prevent HIV and hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. *Int J Drug Policy*. 2014;25(1):34–52.
65. Palmateer NE, Taylor A, Goldberg DJ, Munro A, Aitken C, Shepherd SJ, et al. Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. *PLoS ONE*. 2014;9(8):e104515.
66. Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. *Addiction*. 2010;105(5):844–59.
67. Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV

transmission among people who inject drugs: findings from a cochrane review and meta-analysis. *Addiction*. 2018;113(3):545–63.

68. Pedrana A, Howell J, Schröder S, Scott N, Wilson D, Kuschel C, et al. Eliminating viral hepatitis: the investment case. Doha, Qatar: World Innovation Summit for Health (WISH). <https://www.wish.org.qa/reports/eliminating-viral-hepatitis-the-investment-case/>.
69. Lazarus JV, Safreed-Harmon K, Thursz MR, Dillon JF, El-Sayed MH, Elsharkawy AM, et al. The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations. *Semin Liver Dis*. 2018;38(03):181–92.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

